5-hydroxytryptophan has been researched along with Anankastic Personality in 6 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On the basis of numerous previous studies, the serotonergic system plays a role in the pathogenesis of obsessive-compulsive disorder (OCD) and effective agents in this pathway, such as 5-hydroxytryptophan, can potentially contribute to treatment of patients with this disorder." | 9.34 | 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. ( Akhondzadeh, S; Alikhani, R; Aqamolaei, A; Ghaffari, S; Jalilevand, S; Mortazavi, SH; Mortezaei, A; Mousavi, SB; Naderi, S; Sadri, A; Sahebolzamani, E; Shalbafan, MR; Shamabadi, A; Yousefzadeh, F, 2020) |
| "A double-blind placebo-controlled study of 5-HTP and clomipramine was carried out on 45 patients suffering from anxiety disorders (DSM-III)." | 9.06 | Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. ( Gispen-de Wied, CC; Kahn, RS; Kamerbeek, WD; Verhoeven, WM; Westenberg, HG, 1987) |
| "Clomipramine has shown to be effective in that it induced significant improvement on all rating scales as compared to placebo." | 6.66 | Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. ( Gispen-de Wied, CC; Kahn, RS; Kamerbeek, WD; Verhoeven, WM; Westenberg, HG, 1987) |
| "On the basis of numerous previous studies, the serotonergic system plays a role in the pathogenesis of obsessive-compulsive disorder (OCD) and effective agents in this pathway, such as 5-hydroxytryptophan, can potentially contribute to treatment of patients with this disorder." | 5.34 | 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. ( Akhondzadeh, S; Alikhani, R; Aqamolaei, A; Ghaffari, S; Jalilevand, S; Mortazavi, SH; Mortezaei, A; Mousavi, SB; Naderi, S; Sadri, A; Sahebolzamani, E; Shalbafan, MR; Shamabadi, A; Yousefzadeh, F, 2020) |
| "A double-blind placebo-controlled study of 5-HTP and clomipramine was carried out on 45 patients suffering from anxiety disorders (DSM-III)." | 5.06 | Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. ( Gispen-de Wied, CC; Kahn, RS; Kamerbeek, WD; Verhoeven, WM; Westenberg, HG, 1987) |
| "Clomipramine has shown to be effective in that it induced significant improvement on all rating scales as compared to placebo." | 2.66 | Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. ( Gispen-de Wied, CC; Kahn, RS; Kamerbeek, WD; Verhoeven, WM; Westenberg, HG, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yousefzadeh, F | 1 |
| Sahebolzamani, E | 1 |
| Sadri, A | 1 |
| Mortezaei, A | 1 |
| Aqamolaei, A | 1 |
| Mortazavi, SH | 1 |
| Shalbafan, MR | 1 |
| Ghaffari, S | 1 |
| Alikhani, R | 1 |
| Mousavi, SB | 1 |
| Naderi, S | 1 |
| Shamabadi, A | 1 |
| Jalilevand, S | 1 |
| Akhondzadeh, S | 1 |
| Camfield, DA | 1 |
| Sarris, J | 1 |
| Berk, M | 1 |
| Rojas-Corrales, MO | 1 |
| Gibert-Rahola, J | 1 |
| Mico, JA | 1 |
| Meltzer, H | 1 |
| Bastani, B | 1 |
| Jayathilake, K | 1 |
| Maes, M | 1 |
| Kahn, RS | 2 |
| van Praag, HM | 1 |
| Wetzler, S | 1 |
| Asnis, GM | 1 |
| Barr, G | 1 |
| Westenberg, HG | 1 |
| Verhoeven, WM | 1 |
| Gispen-de Wied, CC | 1 |
| Kamerbeek, WD | 1 |
2 reviews available for 5-hydroxytryptophan and Anankastic Personality
| Article | Year |
|---|---|
Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence.
Topics: 5-Hydroxytryptophan; Acetylcysteine; Dietary Supplements; Glycine; Humans; Hypericum; Inositol; Obse | 2011 |
Serotonin and anxiety revisited.
Topics: 5-Hydroxytryptophan; Animals; Anxiety Disorders; Benzodiazepines; Brain; Humans; Obsessive-Compulsiv | 1988 |
3 trials available for 5-hydroxytryptophan and Anankastic Personality
| Article | Year |
|---|---|
5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control.
Topics: 5-Hydroxytryptophan; Adult; Double-Blind Method; Drug Therapy, Combination; Female; Fluvoxamine; Hum | 2020 |
Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder.
Topics: 5-Hydroxytryptophan; Adult; Age Factors; Antidepressive Agents, Second-Generation; Antidepressive Ag | 1997 |
Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo.
Topics: 5-Hydroxytryptophan; Adult; Agoraphobia; Anxiety Disorders; Clinical Trials as Topic; Clomipramine; | 1987 |
1 other study available for 5-hydroxytryptophan and Anankastic Personality
| Article | Year |
|---|---|
Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior.
Topics: 5-Hydroxytryptophan; Analgesics, Opioid; Animals; Clozapine; Desipramine; Disease Models, Animal; Do | 2007 |